Anterogen.Co.,Ltd. (KOSDAQ:065660)

Market Cap	254.15B
Revenue (ttm)	7.00B
Net Income (ttm)	-2.42B
Shares Out	10.01M
EPS (ttm)	-247.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,851
Average Volume	34,304
Open	25,150
Previous Close	25,400
Day's Range	24,650 - 25,600
52-Week Range	13,700 - 29,650
Beta	0.42
RSI	56.54
Earnings Date	n/a

About Endeavor Group Holdings

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065660

Financial Performance

In 2024, Anterogen.Co.,Ltd.'s revenue was 6.93 billion, an increase of 6.66% compared to the previous year's 6.50 billion. Losses were -2.29 billion, -19.29% less than in 2023.